Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | HTR2A | P28223 | 3/20 | 0.66 |
| ▸ | LTA4H | P09960 | 2/20 | 0.66 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.66 |
| ▸ | HTR1D | P28221 | 6/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | HTR1B | P28222 | 3/20 | 0.59 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.58 |
| ▸ | HTR1A | P08908 | 2/20 | 0.58 |
| ▸ | MPO | P05164 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11768689 | 0.86 | DRD3 (0.58) | TRPM8KDM4EMAPTLTA4HPLA2G2A | |
| Hydrochloric Acid SCHEMBL11767138 | 0.85 | LTA4H (0.59) | TRPM8KDM4EMAPTLTA4HPLA2G2A | |
| SCHEMBL11738116 | 0.84 | HTR6 (0.56) | TRPM8KDM4EMAPTLTA4HPLA2G2A | |
| SCHEMBL2823989 | 0.83 | TRPM8 (0.62) | TRPM8KDM4EMAPTLTA4HPLA2G2A | |
| SCHEMBL11471775 | 0.82 | TRPM8 (0.53) | TRPM8KDM4EMAPTHTR2ALTA4H | |
| SCHEMBL6988545 | 0.81 | HTR1D (0.78) | TRPM8KDM4EMAPTLTA4HPLA2G2A | |
| SCHEMBL27406721 | 0.81 | TRPM8 (0.77) | TRPM8KDM4EMAPTLTA4HPLA2G2A | |
| SCHEMBL6388022 | 0.81 | POLB (0.78) | TRPM8KDM4EMAPTLTA4HPLA2G2A | |
| 5-Benzyloxytryptamine SCHEMBL29785061 | 0.81 | TRPM8 (1.00) | TRPM8KDM4EMAPTLTA4HPLA2G2A | |
| 5-Benzyloxytryptamine SCHEMBL2537373 | 0.81 | TRPM8 (1.00) | TRPM8KDM4EMAPTLTA4HPLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034119-A1 | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE ANALOGS, THEIR SYNTHESIS, AND METHODS FOR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC, AND SUBSTANCE USE DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2026-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034119-A1 | 5-METHOXY-N,N-DIMETHYLTRYPTAMINE ANALOGS, THEIR SYNTHESIS, AND METHODS FOR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC, AND SUBSTANCE USE DISORDERS | HTR4, OPRM1, HTR7 | TRPM8 431/4885KDM4E 1423/4885MAPT 1764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.